Addressing the safety of anakinra in patients with rheumatoid arthritis.

Abstract

Anakinra (Kineret; Amgen Inc., Thousand Oaks, CA) is the first and only recombinant human interleukin-1 receptor antagonist available for therapeutic use. It has been approved by the US Food and Drug Administration and the European Commission for the treatment of patients with rheumatoid arthritis (RA). Anakinra, as an anti-rheumatic therapy, has been… (More)

4 Figures and Tables

Topics

  • Presentations referencing similar topics